China medical device regulatory readiness for NMPA market access

Regulator: National Medical Products Administration (NMPA; formerly CFDA) with technical evaluation by the Center for Medical Device Evaluation (CMDE). Core statute: Order No. 739, Regulations for the Supervision and Administration of Medical Devices (2021). Key supporting measures: Administrative Measures for Registration and Filing of Medical Devices (NMPA Orders 47 and 48, 2021 for devices and IVDs), Special Review Procedure for Innovative Medical Devices (rev. 2020) and Priority Review procedures. Clinical: Good Clinical Practice for Medical Devices (GCP, 2022). Quality: Medical Device Good Manufacturing Practice (China GMP; 2014 main text with 2015 appendices for sterile and implantable). Vigilance: Measures for Administration of Medical Device Adverse Event Monitoring and Re‑evaluation (most recently revised versions in force during 2022–2024), and Recall Measures. UDI: NMPA UDI Rules and implementation notices (2019 onward), with phased expansion 2024–2026. Foreign manufacturers must appoint a China Legal Agent (domestic responsible agent) to interface with NMPA, manage adverse events/recalls, and maintain the registration. NMPA issues the Medical Device Registration Certificate, valid five years; renewal (re‑registration) is required to maintain market access.

China classifies devices by risk: Class I (low), Class II (medium), Class III (high). Classification follows the NMPA Medical Device Classification Catalogs (general devices and separate IVD catalog), with codes driving regulatory controls, clinical evidence expectations, and whether clinical evaluation exemption applies. Many IVD reagents are Class II or III; active implantables and life‑supporting devices are typically Class III. Borderline and novel technologies may require a classification determination with the local authority. Correct classification is essential because it dictates whether CMDE review is required (Class II/III), the scope of mandatory in‑country type testing, and the clinical pathway (exemption list availability varies by catalog entry). Innovative devices may pursue the green‑channel special review if they meet novelty, IP, and clinical value criteria, without altering the assigned class.

Typical path for imported Class II/III: 1) Appoint a Legal Agent in China. 2) Define Product Technical Requirements (PTR; 产品技术要求) in Chinese—these are binding performance and safety specifications used for type testing and form part of the registration. 3) Conduct Type Testing at an NMPA-accredited laboratory in China against applicable GB/YY standards and the PTR; class I may be self-inspected per rules, but imports usually undergo type testing. 4) Clinical evaluation: choose among (a) exemption (if listed in NMPA exemption catalogs), (b) equivalence-based clinical evaluation using literature and comparative analysis to a suitable predicate, or (c) China clinical trial under 2022 GCP with ethics approval and, where required, NMPA trial approvals; CMDE may require trials for Class III or novel risk profiles. 5) Prepare the registration dossier: application forms, legal/authorization docs, type-test reports, risk management report, clinical evaluation report or clinical study report, IFU/label in Chinese, QMS evidence per China GMP, and UDI plan if applicable. 6) CMDE technical review (with potential deficiency letters and clock-stops); 7) NMPA administrative approval and issuance of the Registration Certificate. Innovative/priority pathways provide earlier and more frequent CMDE communications and compressed review windows once accepted. Evidence of home-country marketing authorization is generally expected for standard imported registrations unless proceeding via innovative device procedures with justification.

China enforces Medical Device GMP with focus on management responsibility, design and development (for applicable manufacturers), supplier control, production process validation (notably sterilization and special processes), equipment maintenance, traceability, complaint handling, and vigilance. For overseas manufacturers, ISO 13485 certification is beneficial but not a substitute; NMPA may conduct document reviews or on‑site inspections, especially for higher‑risk devices. Expect scrutiny of process validation to Chinese GB/YY methods, incoming inspection criteria, environmental controls for clean/sterile areas, software validation for production and quality systems, and maintenance of complete Device Master Records and Device History Records reflecting the registered PTR. MDSAP is not formally accepted in lieu of China GMP, but aligned processes reduce inspection risk. Maintain robust change control: certain changes post‑approval require supplemental filings or re‑registration.

China’s UDI requires assignment of UDI-DI and UDI-PI, UDI marking on labels/packaging at applicable levels, and master data submission to the NMPA UDI database. Initial batches covered high-risk Class III; by 2024–2025 most Class II are included, with remaining categories phased by 2026 per NMPA notices. Issuing agencies recognized by NMPA (e.g., GS1) may be used. Label/IFU must be in Simplified Chinese and include device name/model, intended use, key performance indicators, contraindications, manufacturing site, production date/expiry, lot/serial, UDI carrier, storage/transport conditions, after-sales service information, and the Legal Agent’s name/address/phone for imports. eIFU acceptance is limited; paper IFU is the norm unless a product-specific policy allows otherwise. Label content must align exactly with the PTR and type-test reports; inconsistencies trigger CMDE queries.

Holders of NMPA registrations (including overseas MAHs represented by a Legal Agent) must operate a China PMS system: complaint handling, adverse event detection, investigation, and reporting via the national monitoring system. Serious adverse events generally must be reported promptly (commonly within 15 days of awareness; deaths may require faster initial notification per local authority instructions), followed by updates as investigations progress. Maintain periodic risk evaluation reports when required for certain high-risk categories, perform re‑evaluation if risk–benefit changes, and execute recalls per recall measures (Class I/II/III recall levels). Significant post‑approval changes require supplemental filings; the Registration Certificate must be renewed every five years, with renewal applications typically submitted six months before expiry, including performance/quality summaries and any standard updates. UDI and distribution records must support rapid field action and traceability.

Days 0–30: Appoint/confirm a qualified China Legal Agent. Confirm product classification and applicable catalogs; obtain formal written classification if borderline. Map applicable GB/YY standards and draft PTR in Chinese. Gap-assess existing test/clinical evidence vs. Chinese requirements; define clinical pathway (exemption, equivalence, or China trial) and pre‑consult CMDE if innovative/complex. Start Chinese translations of IFU/labels and key dossier sections. Days 31–90: Prepare samples and protocols; book NMPA-accredited lab slots for type testing. Execute any bridging tests needed overseas while awaiting China lab schedules. Build the clinical evaluation report or initiate China GCP trial site and ethics submissions if needed. Compile risk management report aligned to ISO 14971 with China‑specific hazards. Align QMS evidence to China GMP; verify DMR/DHR structures reflect the PTR. Days 91–180: Receive type-test reports; resolve nonconformities. Freeze Chinese labeling to match PTR/test outputs and add UDI plan if in-scope. Complete the dossier (administrative/legal docs, test reports, clinical package, QMS statements). Run internal mock review and respond to predicted CMDE deficiencies. File and prepare for clock‑stops with rapid, documented responses. Stand up PMS/recall SOPs and UDI data upload processes ahead of approval.